VTRS Q1 2025 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.3B-11.2% YoY

Gross Profit

$1.2B35.7% margin

Operating Income

-$2.9B-88.6% margin

Net Income

-$3.0B-93.5% margin

EPS (Diluted)

$-2.55

QoQ Revenue Growth

-7.8%

Cash Flow

Operating Cash Flow

$536M

Free Cash Flow

$459M

Stock-Based Comp.

$55M

Balance Sheet

Total Assets

$38.5B

Total Liabilities

$22.8B

Stockholders' Equity

$15.7B

Cash & Equivalents

$755M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.3B	$3.7B	-11.2%
Gross Profit	$1.2B	$1.5B	-22.8%
Operating Income	-$2.9B	$204M	-1513.5%
Net Income	-$3.0B	$114M	-2770.8%

Revenue Segments

Brands

$2.1B65%

Generics

$1.1B35%

Geographic Segments

Developed Markets Segment

$1.9B58%

Greater China Segment

$556M17%

Emerging Markets Segment

$523M16%

Japan, Australia and New Zealand Segment

$277M9%